RT Journal Article
T1 V Spanish Consensus Conference on Helicobacter pylori infection treatment.
A1 Gisbert, Javier P
A1 Alcedo, Javier
A1 Amador, Javier
A1 Bujanda, Luis
A1 Calvet, Xavier
A1 Castro-Fernández, Manuel
A1 Fernández-Salazar, Luis
A1 Gené, Emili
A1 Lanas, Ángel
A1 Lucendo, Alfredo J
A1 Molina-Infante, Javier
A1 Nyssen, Olga P
A1 Pérez-Aisa, A
A1 Puig, Ignasi
AB Helicobacter pylori infection is very common in the Spanish population and represents the main cause of chronic gastritis, peptic ulcer, and gastric cancer. The last iteration of Spanish consensus guidelines on H. pylori infection was conducted in 2016. Recent changes in therapeutic schemes along with increasing supporting evidence were key for developing the V Spanish Consensus Conference (May 2021). Fourteen experts performed a systematic review of the scientific evidence and developed a series of recommendations that were subjected to an anonymous Delphi process of iterative voting. Scientific evidence and the strength of the recommendation were classified using GRADE guidelines. An eradication therapy, when prescribed empirically, is considered acceptable when it reliably achieves, or preferably surpass, 90% cure rates. Currently, only quadruple therapies (with or without bismuth) and generally lasting 14 days, accomplish this goal in first- and second-line therapies. A non-bismuth quadruple concomitant regimen (proton pump inhibitor, clarithromycin, amoxicillin, and metronidazole) or a quadruple bismuth-based combination (proton pump inhibitor, bismuth, tetracycline, and metronidazole), are recommended as first-line regimens. Rescue therapies after eradication failure and management of H. pylori infection in peptic ulcer disease were also reviewed.
SN 1130-0108
YR 2021
FD 2021
LK https://hdl.handle.net/10668/26774
UL https://hdl.handle.net/10668/26774
LA en
DS RISalud
RD Sep 19, 2025